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Class D OXA-51-like carbapenemases are chro-
mosomally encoded and appear to be intrinsic to
Acinetobacter baumannii [1]. These enzymes are
weak carbapenemases, and it has been suggested
that they only confer carbapenem resistance if an
additional promoter is provided by the insertion
of ISAba1 upstream of the structural gene [2].
Following recent reports in CMI of new variants
of the OXA-51-like subgroup of class D carbape-
nemases [3,4], we wish to report the identiﬁcation
of 11 more novel blaOXA-51-like variants in clinical
isolates of A. baumannii.
A collection of 60 clinical A. baumannii isolates
of diverse worldwide origin was screened for
blaOXA-51-like genes using primers OXA-69A and
OXA-69B, which amplify a 975-bp product con-
taining the entire blaOXA-51-like coding sequence
[5]. Ampliﬁcation products were sequenced on a
3730 DNA Analyzer (Applied Biosystems, War-
rington, UK) and were compared using BLAST
and Multalin software. Isolates producing a band
of c. 2000 bp, as the result of an insertion
upstream of the blaOXA-51-like gene, were re-ana-
lysed using primers preABprom+ [6] and OXA-
69B to produce a 1189-bp product, which was
then sequenced as above.
Sequence comparison revealed 11 novel
blaOXA-51-like sequences, encoding 11 novel
enzymes, designated OXA-79, OXA-80, OXA-82,
OXA-104 and OXA-106–OXA-112 (http://
www.lahey.org/studies/webt.asp). The origins
of the isolates encoding these enzymes are listed
in Table 1. These novel enzymes differ from all
currently known enzymes by between one and
four amino-acids (Table 1), sharing 99% amino-
acid identity. The blaOXA-79, blaOXA-80, blaOXA-106,
blaOXA-107, blaOXA-109, blaOXA-110 and blaOXA-112
genes each differ from the gene encoding the
closest related enzyme by a single nucleotide,
resulting in a single amino-acid change. The
nucleotide sequence of blaOXA-82 differs from
blaOXA-66 by two nucleotides, one of which is
silent (T435 ﬁ A), and blaOXA-111 has three silent
substitutions compared to blaOXA-51 (C90 ﬁ T,
T216 ﬁ A and T507 ﬁ C). The sequences of
blaOXA-104 and blaOXA-108 differ from that of
blaOXA-95 by 11 and ﬁve nucleotides, respectively,
eight (C54 ﬁ T, C369 ﬁ T, A390 ﬁ G, G426 ﬁ A,
C549 ﬁ T, C610 ﬁ T, G720 ﬁ A and G732 ﬁ A)
and one (C328 ﬁ T) of which are silent. All
amino-acid changes were located outside the
class D carbapenemase motifs [7]. All isolates
producing the larger c. 2000-bp product with
primers OXA-69A and OXA-69B also yielded a
1189-bp product with the second set of primers,
indicating that these isolates had an ISAba1
insertion upstream of the blaOXA-51-like gene.
Sequencing conﬁrmed that the blaOXA-79,
blaOXA-80, blaOXA-82 (in both isolates), blaOXA-107
(in all isolates), blaOXA-108, blaOXA-109 and
blaOXA-110 (in both isolates) genes each had an
ISAba1 insertion 7 bp upstream of the structural
gene. A detailed analysis of the genotypic relation-
ships among these isolates and the inﬂuence of the
ISAba1 insertions on the expression of carbapenem
resistance will be published separately.
Since the discovery of OXA-51 in 2004, the
number of related enzymes in this group has now
Table 1. Amino-acid changes resulting in 11 novel
enzymes
Related enzyme Amino-acid change Novel enzyme Origin of isolates
OXA-66 Trp222 ﬁ Gly OXA-79 UK
(T664 ﬁ G)
OXA-66 Pro130 ﬁ Leu OXA-80 UK
(C389 ﬁ T)
OXA-66 Leu167 ﬁ Val OXA-82 Turkey, USA
(C499 ﬁ G)
OXA-95 Phe7 ﬁ Leu OXA-104a USA
(C21 ﬁ A)
Asp117 ﬁ Asn
(G349 ﬁ A)
Lys146 ﬁ Asn
(G438 ﬁ T)
OXA-70 His198 ﬁ Asp OXA-106 Estonia
(C592 ﬁ G)
OXA-69 Leu167 ﬁ Val OXA-107 Poland, Slovenia
(C499 ﬁ G)
OXA-95 Phe7 ﬁ Leu OXA-108a Poland
(C21 ﬁ A)
Ala25 ﬁ Thr
(G73 ﬁ A)
Ala156 ﬁ Thr
(G466 ﬁ A)
Leu167 ﬁ Val
(C499 ﬁ G)
OXA-66 Pro130 ﬁ Gln OXA-109 UK
(C389 ﬁ A)
OXA-69 Ile129 ﬁ Leu OXA-110 Poland
(A385 ﬁ C)
OXA-51 Thr24 ﬁ Ser OXA-111 Belgium
(A70 ﬁ T)
Val48 ﬁ Ala
(T143 ﬁ C)
Lys209 ﬁ Met
(A626 ﬁ T)
OXA-69 Ser246 ﬁ Pro OXA-112 UK
(T736 ﬁ C)
aOXA-104 and OXA-108 are equally distant from OXA-65 and OXA-95, with
Asn225 ﬁ Asp in place of Phe7 ﬁ Leu. Nucleotide changes are listed in paren-
theses.
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increased to at least 39, and they appear to be
ubiquitous in A. baumannii [3,5,7,8]. While the
insertion of ISAba1upstreamof blaOXA-51-like genes
has been associated with resistance to carbapen-
ems, not all isolates contain such an insertion [2].
OXA-51 and OXA-69 have been shown to hydro-
lyse carbapenems poorly [5,7], and it would be of
interest to determine whether the sequence diver-
sity of this group is a result of selection for greater
activity against the carbapenems.
NUCLEOTIDE SEQUENCE
ACCESSION NUMBERS
The novel sequences reported in this study
are deposited in the GenBank nucleotide
database under accession numbers EU019534
(OXA-79), EU019535 (OXA-80), EU019536 (OXA-
82), EF581285 (OXA-104), EF650032 (OXA-106),
EF650033 (OXA-107), EF650034 (OXA-108),
EF650035 (OXA-109), EF650036 (OXA-110),
EF650037 (OXA-111) and EF650038 (OXA-112).
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Mumps vaccine failure or vaccination
scheme failure?
10.1111/j.1469-0691.2007.01811.x
We read with interest the study by Atrasheuskaya
et al. [1] concerning vaccine failure in cases of
mumps during 2002–2004 in Novosibirsk, Russia.
According to Atrasheuskaya et al. [1], the ques-
tion of whether these cases were caused by an
absence of sufﬁcient titres of antibody in response
to vaccination, or were caused by the absence of
neutralising antibody speciﬁc for the causative
mumps virus strain, cannot be answered conclu-
sively. On the basis of lessons learnt from a
descriptive epidemiological investigation of a
mumps outbreak in 214 young adults in Austria
during 2006, we hypothesise that susceptibility to
mumps infection is less likely to result from a
vaccine failure than from a vaccination scheme
failure, i.e., administration of only one of the two
recommended doses of vaccine.
Active immunisation with the Jeryl Lynn
strain of attenuated mumps virus vaccine has
been available in Austria since 1974, when a
bivalent mumps–measles (MM II) vaccine pro-
duced by Merck Sharp & Dohme was introduced
as part of the national childhood immunisation
programme. In 1994, the bivalent vaccine was
replaced by a trivalent mumps, measles and
rubella (MMR) vaccine produced by Pasteur
Merieux Connaught (containing the Jeryl Lynn
strain). Since 2001, the Priorix MMR vaccine
(Glaxo Smith Kline) has been in use, which
contains the RIT 4385 mumps strain derived
from the Jeryl Lynn strain. The vaccination
regimen includes two doses, with the ﬁrst dose
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